Showing 1 – 20 of 40
Best Match | Most Recent | Oldest |
  • Hepatitis C Virus—From Discovery to Cure: The 2016 Lasker-DeBakey Clinical Medical Research Award

    Abstract Full Text
    JAMA. 2016; 316(12):1254-1255. doi: 10.1001/jama.2016.13713

    In this Viewpoint, 2016 Lasker Award winners Ralf Bartenschlager, Charles Rice, and Michael Sofia discuss their work developing a system to study the replication of hepatitis C virus and a class of antivirals to treat the infection.

  • VA Extends New Hepatitis C Drugs to All Veterans in Its Health System

    Abstract Full Text
    JAMA. 2016; 316(9):913-915. doi: 10.1001/jama.2016.8669

    This Medical News article discusses recent efforts by the Department of Veterans Affairs to extend new hepatitis C treatments to all veterans within its health care system.

  • The Need to Expand Access to Hepatitis C Virus Drugs in the Indian Health Service

    Abstract Full Text
    JAMA. 2016; 316(8):817-818. doi: 10.1001/jama.2016.7186

    This Viewpoint calls for government support for providing direct–acting antiviral treatment to American Indian/Alaska Native population, which is disproportionately infected by hepatitis C virus.

  • Hepatitis C Drugs Top State Medicaid Pharmaceutical Expenditures

    Abstract Full Text
    JAMA. 2016; 315(6):549-549. doi: 10.1001/jama.2016.0166
  • Senator Urges VA to “Break” Patents for High-Cost Hepatitis C Drugs

    Abstract Full Text
    JAMA. 2015; 314(2):115-115. doi: 10.1001/jama.2015.7534
  • Warning for Hepatitis C Treatments Given With Amiodarone

    Abstract Full Text
    JAMA. 2015; 313(17):1704-1704. doi: 10.1001/jama.2015.4116
  • Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

    Abstract Full Text
    free access
    JAMA. 2015; 313(12):1232-1239. doi: 10.1001/jama.2015.1373

    This pilot study reports high rates of posttreatment sustained virologic response after use of combined ledipasvir and sofosbuvir among patients co-infected with hepatitis C virus genotype 1 and human immunodeficiency virus.

  • Treatment of Hepatitis C: A Systematic Review

    Abstract Full Text
    is active quiz
    JAMA. 2014; 312(6):631-640. doi: 10.1001/jama.2014.7085

    Kohli and coauthors review the safety, efficacy, and tolerability of current approved interferon-based regimens and oral interferon-free regimens for treating hepatitis C virus infection and provide treatment recommendations for specialists and generalists based on published evidence.

  • New Expensive Treatments for Hepatitis C Infection

    Abstract Full Text
    JAMA. 2014; 312(6):593-594. doi: 10.1001/jama.2014.8897
  • Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

    Abstract Full Text
    free access has multimedia
    JAMA. 2014; 312(4):353-361. doi: 10.1001/jama.2014.7734

    The PHOTON-1 investigators report that, after 12 or 24 weeks of treatment patients coinfected with HIV and hepatitis C virus who received an oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of sustained virologic response.

  • Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics: A Randomized Clinical Trial

    Abstract Full Text
    free access has multimedia
    JAMA. 2013; 310(8):804-811. doi: 10.1001/jama.2013.109309

    To assess the addition of sofosbuvir to ribavirin to treat liver disease in patients with hepatitis C virus, especially among patients with unfavorable treatment characteristics—black race, genotype 1a, advanced liver fibrosis, and obesity—Osinusi and coauthors conducted a 2-part, single-center, randomized open-label trial involving 60 patients. They compared the combination treatment of weight-based or low-dose ribavirin treatment plus 400 mg/d of sofosbuvir for 24 weeks.

  • JAMA

    Figure: Rates of 12-Week Sustained Virologic Response by Subgroup in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving 24 Weeks of Sofosbuvir and Ribavirin

    The position of the solid squares indicates the rate of virologic response 12 weeks after the end of treatment for each subgroup; the horizontal lines indicate 95% confidence intervals. The vertical line represents the overall rate of sustained virologic response (SVR) for all patients with genotype 1. Body mass index is calculated as weight in kilograms divided by height in meters squared. ARV indicates antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; SVR12, sustained virological response for 12 weeks; and ULN, upper limit of normal.
  • JAMA

    Figure: Decline in Median HCV Viral Load After Initiation of Study Drugs, Days 0-28

    Baseline log hepatitis C virus (HCV) viral load was similar in both groups (6.0 [SD, 0.1] IU/mL in patients receiving antiretroviral (ARV) treatment and 6.1 in patients not receiving ARV treatment [SD, 0.3] in [P = .49]). The study drug combination of ledipasvir and sofosbuvir was equally effective in patients not receiving and receiving ARV treatment (P = .78 for total effectiveness). Lower limit of quantification is 12 IU/mL.
  • New Drug Targets All 6 HCV Types

    Abstract Full Text
    JAMA. 2016; 316(7):703-703. doi: 10.1001/jama.2016.10682
  • The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform

    Abstract Full Text
    is active quiz has multimedia
    JAMA. 2016; 316(8):858-871. doi: 10.1001/jama.2016.11237

    This Special Communication summarizes published evidence about the causes of elevated prescription drug prices in the United States and proposes policy options to mitigate the effects of high prices while preserving incentives for development and innovation.

  • Hepatitis C Treatment Delivery Mandates Optimizing Available Health Care Human Resources: A Case for Task Shifting

    Abstract Full Text
    JAMA. 2016; 315(18):1947-1948. doi: 10.1001/jama.2016.1993

    This Viewpoint describes how a shortage of health care workers providing treatment for hepatitis C hinders access to treatment, despite progress in drug efficacy and reductions in drug costs.

  • Drug-Drug Interactions in Patients Co-infected With HCV and HIV

    Abstract Full Text
    JAMA. 2015; 314(2):186-186. doi: 10.1001/jama.2015.6618
  • Drug-Drug Interactions in Patients Co-infected With HCV and HIV—Reply

    Abstract Full Text
    JAMA. 2015; 314(2):186-187. doi: 10.1001/jama.2015.6621
  • Treatment for HCV Genotypes 3 and 4

    Abstract Full Text
    JAMA. 2015; 314(9):867-867. doi: 10.1001/jama.2015.10492
  • New Therapies in the Treatment of High Cholesterol: An Argument to Return to Goal-Based Lipid Guidelines

    Abstract Full Text
    JAMA. 2015; 314(14):1443-1444. doi: 10.1001/jama.2015.10017

    This Viewpoint discusses the need to achieve consensus around management strategies for patients with hyperlipidemia when proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors enter the marketplace.